Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SGHT 
Sight Sciences Inc (SGHT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: SGHT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.85
1 Year Target Price $7.85
| 2 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.82% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 428.26M USD | Price to earnings Ratio - | 1Y Target Price 7.85 |
Price to earnings Ratio - | 1Y Target Price 7.85 | ||
Volume (30-day avg) 8 | Beta 2.41 | 52 Weeks Range 2.03 - 8.80 | Updated Date 12/14/2025 |
52 Weeks Range 2.03 - 8.80 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.63% | Operating Margin (TTM) -25.65% |
Management Effectiveness
Return on Assets (TTM) -20.47% | Return on Equity (TTM) -57.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 376573021 | Price to Sales(TTM) 5.63 |
Enterprise Value 376573021 | Price to Sales(TTM) 5.63 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA -4.25 | Shares Outstanding 52871731 | Shares Floating 29289353 |
Shares Outstanding 52871731 | Shares Floating 29289353 | ||
Percent Insiders 20.65 | Percent Institutions 49.61 |
About Sight Sciences Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2021-07-15 | Co-Founder, President, CEO & Director Mr. Paul Badawi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 216 | Website https://www.sightsciences.com |
Full time employees 216 | Website https://www.sightsciences.com | ||
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.